The first trial against Teva Pharmaceutical Industries stemming from a mass outbreak of hepatitis C at a Las Vegas clinic began Monday. The plaintiff and hundreds of other patients were allegedly infected at the clinic two years ago because nurses reused vials of the anesthetic propofol.
After settling with medical personnel, the plaintiff’s lawyers hope to prove that Teva didn’t do enough to warn medical professionals of the danger for contamination if the vials were reused. A 1995 study published in the New England Journal of Medicine found a large potential for contamination of propofol in the clinical setting. From the Las Vegas Review-Journal:
Teva was aware of the potential danger, having logged 148 previous hepatitis C infections blamed on reuse of single-use vials of propofol, [Robert Eglet, the plaintiff’s lawyer] said. “They knew it was a problem. They knew there was multidosing with these vials.”
A spokeswoman from Teva denied responsibility for the outbreak, according to the Review-Journal, saying the company’s products carried warnings against reuse. The trial is being closely watched by other patients who have filed lawsuits related to the outbreak.


